What is LGS? Parent Driven Data from the Natural History Project



LENNOX-GASTAUT SYNDROME

Anne T. Berg, PhD Lurie Children's Hospital Chicago, Il

Lennox-Gastaut Syndrome Defined?

Child neurology foundation

- Childhood
- Multiple seizure types; most common: tonic, atypical absence and "drop attacks."
 - also generalized tonic-clonic and focal seizures as well.
- EEG: high voltage, GSW (<2.5 Hertz), generalized PFA in sleep, waking background slow and disorganized.
- Moderate to severe cognitive disabilities are common
- Multiple different causes, many unknown

• <u>ILAE</u>

- Onset of seizure 1-7 years (peak 3-5 year)
- <u>Tonic seizures ~mandatory</u>, + atonic & atypical absence
- Slow spike&wave
- Cognitive impairment
- Multiple different causes, many unknown

Lennox-Gastaut Syndrome Defined?

- In the literature (Camfield, Epilepsia 2011)
 - Tonic seizures required for the diagnosis (Arzimanoglou et al., 2009),
 - + myoclonic, atypical absence, nonconvulsive status
 - Slow spike&wave (<2.5 Hz)
 - profound deleterious effects on intellectual and psychosocial function

In Major RCTs:

- Glauser, RUF (Neurology, 2008)
 - atypical absence seizures and drop attacks (i.e., tonic—atonic or astatic seizures) +/others
 - EEG with slow spike-and-wave complexes (2.5 Hz) within 6 months of study entry
- Devinsky, CBD (NEJM, 2018)
 - Slow spike-and-wave complexes <3 hz
 - >two types of generalized seizures, including drop seizures (atonic, tonic, or tonic—clonic) involving the entire body, trunk, or head leading to to fall, injury, or slumping in chair.

The Natural History Project



Home Page

Welcome to the Natural History Study!





To register for a new study or continue with an ongoing study, click here.



For the Medical Practitioner & Researcher



Study Results



Supported by the Stanley Manne Children's Research Institute, Ann & Robert H. Lurie Children's Hospital of Chicago under the Precision Medicine Strategic Research Initiative and the Pediatric Epilepsy Research Foundation (PERF).




How is this different?

- Designed with and by parents and content experts
- More than a check-list
- Intent is to quantify
 - Nature
 - Frequency
 - Severity
 - Variability
- Report results back to the family groups
 - On group website, webinars
 - Dissemination to the family, scientific, and provider communities




Lennox Gastaut Syndrome

The Natural History Project



Available on LGSF website and at https://theability.study/

Seizure types




Age at onset


- 6 months median
 - As young as day 1
 - Oldest 6 years
 - 90% by ~3 years



• From diagnosis of epilepsy to diagnosis of LGS - ~2 years



Seizure Frequency



Triggers and predictability


- 58% have some trigger for seizures
 - 45% with illness or temperature change
 - 26% with visual stimulation
 - 26% emotional excitement




• 51% - moderate to a lot of unpredictability in seizure occurrence

Seizures and Sleep









Monitoring sleep

- 81% currently monitor child's sleep
 - 64% video monitoring
 - 32% co-sleeping
 - 27% audio monitoring
 - 23% SAMI movement monitor
 - 18% pulse oximetry
 - 14% Service dog





Seizure Emergencies



• 82% ever have had a seizure or seizure cluster >10 minutes

- In the previous 6 months
 - 1/3 had prolonged seizures
 - 30% went to the ED at least once*
 - 15% went multiple times



Seizure Emergencies

- 51% used any rescue medications*
 - 27% used rescue meds 1-9 time*
 - 24% used rescue meds ≥10 times*
 - Of those reporting rescue medication use:
 - 30% said a second dose was often needed
 - 25% said a second dose was always needed
- Most common rescue medications: Klonopin and Diastat©



- 45% used bridge medications at least once*
 - 24% used bridge meds 1-4 times
 - 21% used bridge meds 5 or more time

Seizure Emergencies

- Currently, 57% have a seizure rescue plan
- Who didn't have a rescue plan?
 - 30% with recent prolonged seizures
 - 38% of those who went to the ED one or more times
 - 50% of those who used bridge meds one or more times
 - 53% of those who used rescue meds one or more times



Lennox-Gastaut Syndrome Defined?

Child neurology foundation

- Childhood
- Multiple seizure types; most common: tonic, atypical absence and "drop attacks."
 - also generalized tonic-clonic and focal seizures as well.
- EEG: high voltage, GSW (<2.5 Hertz), generalized PFA in sleep, waking background slow and disorganized.
- Moderate to severe cognitive disabilities are common
- Multiple different causes, many unknown

• ILAE

- Onset of seizure 1-7 years (peak 3-5 year)
- <u>Tonic seizures ~mandatory</u>, + atonic & atypical absence
- Slow spike&wave
- Cognitive impairment
- Multiple different causes, many unknown
- In the literature (Camfield, Epilepsia 2011)
 - <u>Tonic seizures required</u> for the diagnosis (Arzimanoglou et al., 2009),
 - + myoclonic, atypical absence, nonconvulsive status
 - Slow spike&wave (<2.5 Hz)
 - profound deleterious effects on intellectual and psychosocial function

Beyond Seizures — Basic Functional Abilities




31% require a mobility device at home or school

25% typically do not manipulate objects with their hands.



50% do not use spoken language





42% cannot feed themselves Including 29% with G-tubes



54% inconsistently or rarely communicate even with people they know (e.g. family)

What can young people with LGS do?



50% use a

touch-

screen

device

38% use spoon and fork



42% drink from an open cup



30% have simple academic skills




46% scribble or draw with a crayon or pencil




25% brush their own teeth



17% are completely independent for toilet use







21% dress themselves

Behavior

Autism


- 35% diagnosed
- 23% features

Anxiety

- 19% diagnosed
- 8% features

ADHD

- 27% Diagnosed
- 4% features




>1/2





Behavior



Pastimes

Singing songs
Listening to music
Being sung to









Playing with water

Healthcare Team — Currently involved

Therapists



- **74%** Speech
- **70**% Occupational
- **57%** Physical
- 17% Behavioral
- 9% Psychologist
- **9**% Developmental



Medical Specialists

- 96% Neurologist
- 43% Special Needs Dentist
- 43% Orthopedist
- 30% Neurosurgeon
- 26% Ophthalmologist
- 17% Dermatologist
- 17% Dietician
- 17% Gastroenterologist
- 9% Cardiologist
- 9% Geneticist



Healthcare burden

6 median number of different therapists and medical specialists involved in care








43% Of parent coordinates

Of parents feel care is not well coordinated across specialists





Of children have 2 or more therapy appointments per week





Impact on siblings

63% Limited attention to other children





69% Other children had to grow up faster

Other children resented ill sibling?

67% not at all



70% have other children

About siblings


Adult children still have needs, I can't respond to them. Guilt is overwhelming.

Our daughter is a preschool intervention specialist. The choice was definitely influenced by her sibling.

Our other children's career choices have definitely been affected by their sibling's epilepsy.

Impact on parents

82% say life feels like a rollercoaster





78% report moderate to severe fatigue



The Natural History Study

- Defined the landscape of Lennox-Gastaut syndrome
 - What is moderate to severe disability?
 - What does that mean?
 - What are the abilities to build on?



FDA and Natural History

Rare Diseases: Common Issues in Drug Development Guidance for Industry

2012,...2019

Define the disease population, including a description of the <u>full range of disease</u> manifestations and identification of important disease subtypes. This may allow selection of patients more likely to progress and develop the endpoints assessed in the context of a clinical trial (prognostic enrichment).



Table S3: Other Secondary Outcomes

Appendix Pg16/18

		Cannabidiol,	Cannabidiol,	Cannabidiol,	Cannabidiol,
Outcome	Placebo	10 mg/kg/d	20 mg/kg/d	10 mg/kg/d vs. Placebo	20 mg/kg/d vs. Placebo
Percentage with $\geq 25\%$,		0 0		5 5	
$\geq 75\%$, and 100%					
reduction from baseline					
in drop-seizure frequency	n/N (%)	n/N (%)	n/N (%)	Odds Ratio (95% CI)	Odds Ratio (95% CI)
≥ 25% reduction	33/76 (43.4)	46/73 (63.0)	47/76 (61.8)	2.22 [†] (1.15 to 4.28)	2.11 [†] (1.10 to 4.04)
≥ 75% reduction	2/76 (2.6)	8/73 (11.0)	19/76 (25.0)	4.55† (0.93 to 22.22)	12.33 [†] (2.76 to 55.13)
100% reduction	0/76 (0)	0/73 (0)	0/76 (0)	N/A	N/A
Percentage experiencing	, ,	, ,	` ,		
worsening or					
improvements in drop					
seizure frequency during					
the treatment period	n/N (%)	n/N (%)	n/N (%)		
> 25% worsening	7/76 (9.2)	7/73(9.6)	10/76 (13.2)		
\geq 0% to \leq 25% worsening	15/76 (19.7)	7/73 (9.6)	8/76 (10.5)		
> 0% to < 25%					
improvement	21/76 (27.6)	13/73 (17.8)	11/76 (14.5)		
\geq 25% to < 50%					
improvement	22/76 (28.9)	20/73 (27.4)	17/76 (22.4)		
\geq 50% to < 75%					
improvement	9/76 (11.8)	18/73 (24.7)	11/76 (14.5)		
≥ 75% improvement	2/76 (2.6)	8/73 (11.0)	19/76 (25.0)		
Percentage reduction					
from baseline in seizure					
frequency (average per					
28 days) during the				Estimated Median	Estimated Median
treatment period	N	N	N	Difference (95% CI) ^a	Difference (95% CI) ^a
treatment period Non-drop seizures	70	55	64	Difference (95% CI) ^a 28.31 [†] (10.54 to 43.75)	Difference (95% CI) ^a 22.36 [†] (2.22 to 40.10)
Non-drop seizures Convulsive seizures	70 76	55 73	64 76	Difference (95% CI) ^a 28.31 [†] (10.54 to 43.75) 22.08 [†] (10.42 to 33.48)	Difference (95% CI) ^a 22.36 [†] (2.22 to 40.10) 18.58 [†] (5.45 to 31.11)
Non-drop seizures Convulsive seizures Nonconvulsive seizures	70 76 60	55 73 45	64 76 59	Difference (95% CI) ^a 28.31 [†] (10.54 to 43.75) 22.08 [†] (10.42 to 33.48) 16.62 [†] (-3.39 to 37.77)	Difference (95% CI) ^a 22.36 [†] (2.22 to 40.10) 18.58 [†] (5.45 to 31.11) 18.87 [†] (0.00 to 40.22)
Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures	70 76 60 57	55 73 45 56	64 76 59 59	Difference (95% CI) ^a 28.31 [†] (10.54 to 43.75) 22.08 [†] (10.42 to 33.48) 16.62 [†] (-3.39 to 37.77) 21.78 [†] (7.36 to 35.90)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02)
Treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures	70 76 60 57 41	55 73 45 56 40	64 76 59 59 50	Difference (95% CI) ^a 28.31 [†] (10.54 to 43.75) 22.08 [†] (10.42 to 33.48) 16.62 [†] (-3.39 to 37.77) 21.78 [†] (7.36 to 35.90) 28.77 [†] (7.08 to 45.55)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79)
Treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures	70 76 60 57	55 73 45 56	64 76 59 59	Difference (95% CI) ^a 28.31 [†] (10.54 to 43.75) 22.08 [†] (10.42 to 33.48) 16.62 [†] (-3.39 to 37.77) 21.78 [†] (7.36 to 35.90)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02)
Treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in	70 76 60 57 41	55 73 45 56 40	64 76 59 59 50	Difference (95% CI) ^a 28.31 [†] (10.54 to 43.75) 22.08 [†] (10.42 to 33.48) 16.62 [†] (-3.39 to 37.77) 21.78 [†] (7.36 to 35.90) 28.77 [†] (7.08 to 45.55)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79)
Treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver	70 76 60 57 41	55 73 45 56 40	64 76 59 59 50	Difference (95% CI) ^a 28.31 [†] (10.54 to 43.75) 22.08 [†] (10.42 to 33.48) 16.62 [†] (-3.39 to 37.77) 21.78 [†] (7.36 to 35.90) 28.77 [†] (7.08 to 45.55)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79)
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of	70 76 60 57 41	55 73 45 56 40	64 76 59 59 50	Difference (95% CI) ^a 28.31 [†] (10.54 to 43.75) 22.08 [†] (10.42 to 33.48) 16.62 [†] (-3.39 to 37.77) 21.78 [†] (7.36 to 35.90) 28.77 [†] (7.08 to 45.55)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79)
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure	70 76 60 57 41 34	55 73 45 56 40 37	64 76 59 59 50 41	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99)
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b	70 76 60 57 41 34	55 73 45 56 40 37	64 76 59 59 50 41	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures	70 76 60 57 41 34 N	55 73 45 56 40 37 N	64 76 59 59 50 41 N 50	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09)
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures	70 76 60 57 41 34 N 48 35	55 73 45 56 40 37 N 49 38	64 76 59 59 50 41 N 50 43	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30) 2.78† (1.11 to 6.96)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09) 1.90† (0.79 to 4.55)
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures Atonic seizures Tonic-clonic seizures	70 76 60 57 41 34 N	55 73 45 56 40 37 N	64 76 59 59 50 41 N 50	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09)
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures Atonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures Change from baseline in	70 76 60 57 41 34 N 48 35	55 73 45 56 40 37 N 49 38	64 76 59 59 50 41 N 50 43	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30) 2.78† (1.11 to 6.96)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09) 1.90† (0.79 to 4.55)
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures Atonic seizures Change from baseline in sleep disruption 0–10	70 76 60 57 41 34 N 48 35	55 73 45 56 40 37 N 49 38	64 76 59 59 50 41 N 50 43	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30) 2.78† (1.11 to 6.96) 2.74† (1.03 to 7.32)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09) 1.90† (0.79 to 4.55) 1.79† (0.67 to 4.74)
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures Atonic seizures Change from baseline in sleep disruption 0–10 numerical rating scale	70 76 60 57 41 34 N 48 35 33	55 73 45 56 40 37 N 49 38 34	64 76 59 59 50 41 N 50 43 34	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30) 2.78† (1.11 to 6.96) 2.74† (1.03 to 7.32) Adjusted Mean	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09) 1.90† (0.79 to 4.55) 1.79† (0.67 to 4.74) Adjusted Mean
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures Atonic seizures Tonic elonic seizures Change from baseline in sleep disruption 0–10 numerical rating scale score	70 76 60 57 41 34 N 48 35 33	55 73 45 56 40 37 N 49 38 34	64 76 59 59 50 41 N 50 43 34	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30) 2.78† (1.11 to 6.96) 2.74† (1.03 to 7.32) Adjusted Mean Difference (95% CI) ^d	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09) 1.90† (0.79 to 4.55) 1.79† (0.67 to 4.74) Adjusted Mean Difference (95% CI) ^d
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures Atonic seizures Change from baseline in sleep disruption 0–10 numerical rating scale seore Last visit	70 76 60 57 41 34 N 48 35 33	55 73 45 56 40 37 N 49 38 34	64 76 59 59 50 41 N 50 43 34	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30) 2.78† (1.11 to 6.96) 2.74† (1.03 to 7.32) Adjusted Mean	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09) 1.90† (0.79 to 4.55) 1.79† (0.67 to 4.74) Adjusted Mean
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures Atonic seizures Change from baseline in sleep disruption 0–10 numerical rating scale seore Last visit Change from baseline in	70 76 60 57 41 34 N 48 35 33	55 73 45 56 40 37 N 49 38 34	64 76 59 59 50 41 N 50 43 34	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30) 2.78† (1.11 to 6.96) 2.74† (1.03 to 7.32) Adjusted Mean Difference (95% CI) ^d -0.8† (-1.7 to 0.1)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09) 1.90† (0.79 to 4.55) 1.79† (0.67 to 4.74) Adjusted Mean Difference (95% CI) ^d -0.3† (-1.2 to 0.6)
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures Atonic seizures Change from baseline in sleep disruption 0–10 numerical rating scale score Last visit Change from baseline in Epworth Sleepiness Scale	70 76 60 57 41 34 N 48 35 33	55 73 45 56 40 37 N 49 38 34	64 76 59 59 50 41 N 50 43 34	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30) 2.78† (1.11 to 6.96) 2.74† (1.03 to 7.32) Adjusted Mean Difference (95% CI) ^d -0.8† (-1.7 to 0.1) Adjusted Mean	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09) 1.90† (0.79 to 4.55) 1.79† (0.67 to 4.74) Adjusted Mean Difference (95% CI) ^d -0.3† (-1.2 to 0.6) Adjusted Mean
treatment period Non-drop seizures Convulsive seizures Nonconvulsive seizures Tonic seizures Atonic seizures Tonic-clonic seizures Change from baseline in the patient/caregiver global impression of change in seizure duration ^b Tonic seizures Atonic seizures Atonic seizures Change from baseline in sleep disruption 0–10 numerical rating scale seore Last visit Change from baseline in	70 76 60 57 41 34 N 48 35 33	55 73 45 56 40 37 N 49 38 34	64 76 59 59 50 41 N 50 43 34	Difference (95% CI) ^a 28.31† (10.54 to 43.75) 22.08† (10.42 to 33.48) 16.62† (-3.39 to 37.77) 21.78† (7.36 to 35.90) 28.77† (7.08 to 45.55) 39.92† (19.66 to 64.55) Odds Ratio (95% CI) ^c 2.75† (1.20 to 6.30) 2.78† (1.11 to 6.96) 2.74† (1.03 to 7.32) Adjusted Mean Difference (95% CI) ^d -0.8† (-1.7 to 0.1)	Difference (95% CI) ^a 22.36† (2.22 to 40.10) 18.58† (5.45 to 31.11) 18.87† (0.00 to 40.22) 18.67† (1.62 to 35.02) 16.98† (-8.52 to 37.79) 27.95† (2.86 to 51.99) Odds Ratio (95% CI) ^c 1.38† (0.62 to 3.09) 1.90† (0.79 to 4.55) 1.79† (0.67 to 4.74) Adjusted Mean Difference (95% CI) ^d -0.3† (-1.2 to 0.6)

The NEW ENGLAND JOURNAL of MEDICINE

ORIGINAL ARTICLE

Effect of Cannabidiol on Drop Seizures in the Lennox–Gastaut Syndrome

Orrin Devinsky, M.D., Anup D. Patel, M.D., J. Helen Cross, M.B., Ch.B., Ph.D., Vicente Villanueva, M.D., Ph.D., Elaine C. Wirrell, M.D., Michael Privitera, M.D., Sam M. Greenwood, Ph.D., Claire Roberts, Ph.D., Daniel Checketts, M.Sc., Kevan E. VanLandingham, M.D., Ph.D., and Sameer M. Zuberi, M.B., Ch.B., M.D., for the GWPCARE3 Study Group*

Pg17/18

		Cannabidiol,	Cannabidiol,	Cannabidiol,	Cannabidiol,
Outcome	Placebo	10 mg/kg/d	20 mg/kg/d	10 mg/kg/d vs. Placebo	20 mg/kg/d vs. Placebo
Change from baseline in					
Quality of Life in)				
Childhood Epilepsy)				
overall quality of life				Adjusted Mean	Adjusted Mean
score	N	N	N	Difference (95% CI) ^d	Difference (95% CI) ^d
End of treatment	38	36	33	1.6 [†] (-4.5 to 7.8)	-5.1 (-11.4 to 1.2)
Change from baseline in					
Vineland Adaptive					
Behavior Scales (Second	١				
Edition) Adaptive	/				
Behavior Composite				Adjusted Mean	Adjusted Mean
Standard Score	N	N	N	Difference (95% CI) ^d	Difference (95% CI) ^d
Last visit	45	23	39	0.5 [†] (-1.3 to 2.3)	0.1 [†] (-1.4 to 1.6)

FDA and Natural History & Trial Readiness

Rare Diseases: Common Issues in Drug Development Guidance for Industry

2012,...2019

Define the disease population, including a description of the <u>full range of disease</u> manifestations and identification of important disease subtypes. This may allow selection of patients more likely to progress and develop the endpoints assessed in the context of a clinical trial (prognostic enrichment).

Select clinical endpoints and develop sensitive and specific outcome measures.



The Ability Study

- ~10 days in February, 2020
- 135 parents participated
 - 39 from LGSF!!!




- 42 Dravet syndrome
- 20 KCNB1 Families
- 23 KCNQ2 Cure Alliance
- 10 SCN2A Families
- 1 other

Mobility

Select clinical endpoints and develop sensitive and specific outcome measures.

TYPICAL



DEE World



Communication

Select clinical endpoints and develop sensitive and specific outcome measures.


TYPICAL

mamama









FDA and Natural History & Trial Readiness

Rare Diseases: Common Issues in Drug Development Guidance for Industry

2012,...2019

Define the disease population, including a description of the <u>full range of disease</u> manifestations and identification of important disease subtypes. This may allow selection of patients more likely to progress and develop the endpoints assessed in the context of a clinical trial (prognostic enrichment).


Select clinical endpoints and develop sensitive and specific outcome measures.

Conduct a study of sufficient duration to capture clinically meaningful outcomes and variability in the course of the disease.



On-going projects

- Dravet Syndrome Foundatior
 - Longitudinal study of Gait



- FamilieSCN2A
 - Longitudinal study of mobility, communication, and behavior



What would you like to learn from a Natural History study?

Are there differences between seizure activity and response to medication for kids that have no know cause of LGS as compared to those with an identified cause?

How to prevent other families from having to go through this.

I would like to have an understanding of severity-like a scale or a continuum to help with perspective.

What do we do with children that are obviously so 'broken' and what are we going to do for their family that is carrying such a big burden

The common areas of struggle that we all share but aren't aware of the commonalities would make families feel less alone.

I would like to know that I have been able to help other families that are new to epilepsy

Hoping medical professionals will learn more about what happens from a patient's point of view and be more understanding.

sleep and behavior are hot topics for families.

need to do more work on effect on siblings...for example, how many have anxiety or some other trauma related issue?

incredibly Important persistent remotes,laptops usually non-verbal none friendly electronics challenges multiple clean entertaining describe understand